Status:
UNKNOWN
Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites
Lead Sponsor:
Hui ting Xu，MD
Conditions:
Malignant Ascites
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
This study makes an observation over the objective response rate of autologous erythrocytes derived microparticles packaging methotrexate peritoneal perfusion and systemic therapy combination in the t...
Detailed Description
As a drug carrier, erythrocytes have their own advantages, such as high biocompatibility, high immune compatibility, simple structure and easy access. In this study, microparticles released from eryth...
Eligibility Criteria
Inclusion
- 18 and ≤ 80 years of age
- Histological confirmed gastric cancer, colorectal cancer, or ovarian cancer, tumor cells were detected by exfoliative cytology of peritoneal effusion, refractory or recurrent ascites of ovarian cancer were required, other kinds of cancer were not limited
- Vital signs were stable, Karnofsky ≥ 70, life expectancy of more than 3 months
- The hematopoietic function of bone marrow was normal without bleeding tendency (INR \< 1.5), blood routine examination: HGB ≥ 90 g/L, WBC \> 4.0 × 10\^9/L (NEU ≥ 1.5 × 10\^9/L), PLT ≥ 80 × 10\^9/L
- Liver function: STB ≤ 1.5 ULN, AST and ALT≤ 2.5 ULN (if the abnormity of liver function was mainly caused by tumor invasion, AST and ALT ≤ 5 ULN), ALP ≤ 1.5 ULN
- Renal function: BUN and Cr ≤ 1.5 ULN, CCr ≥ 50mL/min
- ECG and blood glucose level were normal
- Patients or family members agreed to participate in the study and signed informed consent
- No other serious heart and lung disease, etc.
Exclusion
- Pregnant or lactating women
- Allergic constitution and multi-drug allergy
- Serious heart, lung, liver and kidney dysfunction, decompensated heart, lung, kidney, liver and other major organs dysfunction or failure, poor blood glucose control, chemotherapy intolerance, combined intestinal obstruction
- Concurrent severe infection
- HIV positive, HBsAg and HBV DNA copy number positive (quantitative detection ≥ 1000 cps/mL), chronic hepatitis C blood screening positive (HCV antibody positive)
- Cognitive impairment or poor chemotherapy compliance determined by investigator
- Less than 4 weeks from the last clinical trial
- Unsuitable for clinical trials determined by investigator
Key Trial Info
Start Date :
May 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2018
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT03230708
Start Date
May 1 2017
End Date
February 1 2018
Last Update
July 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hui ting Xu
Wuhan, Hubei, China, 027